News
Industry Updates
Marketing
Business
FSD Pharma to start selling medical cannabis at Ontario facility
June 24, 2019 By Grow Opportunity staff
FSD Pharma, through its subsidiary FV Pharma, has received its full sale for medical purpose licence to sell cannabis under the Cannabis Act, effective as of June 21, 2019, the company has announced.
The latest amendment to the licence, originally granted last April, allows the FSD facility in Cobourg, Ont., to supply and sell cannabis products, including dried and fresh cannabis to the medicinal use marketplace. FV Pharma can now begin delivering cannabis to patients who hold prescriptions from authorized health-care providers, the licence holder said.
“Achieving this final step in the sales licensing process is much awaited positive news for all of our shareholders and stakeholders. I am grateful for their continued support and patience,” Dr. Raza Bokhari, FSD Pharma executive co-chairman and CEO, said in a statement. “Everyone at our Cobourg facility has worked diligently under the leadership of Dr. Sara May, who deserves special recognition for her commitment to excellence. We can now serve the needs of patients who rely on medicinal cannabis products to manage a range of illnesses and diseases.”
In his statement, Bokhari acknowledged the “vision and missionary commitment” of the company’s founders Zeeshan Saeed and Anthony Durkacz. “I am thankful for their support and the vote of confidence of the entire FSD Pharma board of directors, as we begin writing the next chapters of the FSD Pharma story.”
FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The company currently has 25,000 square feet of licensed space at its Ontario facility and plans are underway for further expansion. FSD facilities sit on 70 acres of land with 40 acres primed for development, and an expansion capability of up to 3.9 million square feet by 2025.
Print this page
